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Abstract
Background and Aims: Secondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel
disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet
generation. In this study we tested the effect of iron therapy on platelet counts in patients with IBD-associated anemia.
Methods: Platelet counts were analyzed before and after iron therapy from four prospective clinical trials. Further, changes
in hemoglobin, transferrin saturation, ferritin, C-reactive protein, and leukocyte counts, before and after iron therapy were
compared. In a subgroup the effect of erythropoietin treatment was tested. The results were confirmed in a large
independent cohort (FERGIcor).
Results: A total of 308 patient records were available for the initial analysis. A dose-depended drop in platelet counts (mean
425 G/L to 320 G/L; p,0.001) was found regardless of the type of iron preparation (iron sulphate, iron sucrose, or ferric
carboxymaltose). Concomitant erythropoietin therapy as well as parameters of inflammation (leukocyte counts, C-reactive
protein) had no effect on the change in platelet counts. This effect of iron therapy on platelets was confirmed in the
FERGIcor study cohort (n=448, mean platelet counts before iron therapy: 383 G/L, after: 310 G/L, p,0.001).
Conclusion: Iron therapy normalizes elevated platelet counts in patients with IBD-associated anemia. Thus, iron deficiency is
an important pathogenetic mechanism of secondary thrombocytosis in IBD.
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Introduction
Platelets (thrombocytes) are small anuclear cell fragments that
derive from mature megakaryocytes. Adult humans produce about
100 billion thrombocytes per day. The primary role of
thrombocytes in mammalians is to ensure hemostasis by binding
to von-Willebrand factor and fibrinogen. In addition, platelets are
a source of pro-inflammatory and anti-microbial mediators [1–3].
An increase in the circulating number of platelets, i.e. thrombo-
cytosis, may occur under certain circumstances such as neoplastic
proliferative diseases (i.e. essential thrombocytosis) or secondary to
other conditions such as hypo- or asplenism, but is also found with
acute and chronic inflammation, malignant disease, blood loss or
iron deficiency [4]. Except for hypo- or asplenism, the mechanism
underlying secondary thrombocytosis and its clinical significance
are not completely understood. Enhanced megakaryopoiesis may
result from an increase of megakaryocytic growth factors such as
thrombopoietin, interleukin (IL)-3, IL-6 or IL-11 [5]. However,
the data on this are vague and further investigation of this topic is
needed.
About one third of patients with inflammatory bowel disease
(IBD) suffer from anemia [6–9]. IBD-associated anemia is caused
by a combination of anemia of chronic disease and iron deficiency
[10]. Accordingly, guidelines recommend iron replacement in
combination with anti-inflammatory drugs and/or erythropoietin
[11,12]. Secondary thrombocytosis is another clinical feature of
IBD that has been associated with active disease [13]. Some
authors propose that activated platelets are involved in the
pathogenesis of IBD [14,15]. So far the relative importance of iron
deficiency for IBD-associated thrombocytosis has not been
elucidated. Here we tested the effect of iron therapy on changes
in platelet counts in two large cohorts of patients with IBD-
associated anemia.
Results
The initial cohort consisted of a total of 323 patients (40 from
the Crohn study, 20 from the Colitis Study, 63 from the Predict
Study, and 200 from the Ferric carboxymaltose Study, Figure 1).
From 308 patients platelets data were available for analysis.
Patients were further divided into ‘‘intravenous iron’’ (three dose
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3600 mg iron’’) and ‘‘oral iron’’ (200 mg per day). Overall, the
mean (SD) platelet counts dropped from 425 (153) G/L at study
entry to 320 (101) G/L after iron treatment (table 1, p,0.001).
This effect was observed with both intravenous (iron sucrose or
ferric carboxymaltose) and oral (iron sulphate) iron products
(figure 2A) and was dose-dependent (figure 2B, p=0.002).
Hemoglobin, transferrin saturation and ferritin improved as
expected, C-reactive protein and leukocyte counts did not change
(table 1).
In the ‘‘Crohn study’’ patients had been randomized to
erythropoietin or placebo treatment but all patients had received
iron sucrose. To test whether erythropoietin may interfere with the
drop in platelet counts, the two treatment groups were compared
and serum erythropoietin levels were analyzed every week.
Platelets dropped to a similar extent and speed in the
erythropoietin and the placebo group (average change in platelet
counts per week 23.7% [95% CI 22.5, 24.9] versus 24.0%
[23.0, 25.0]; p=0.703) despite different changes of serum
erythropoietin levels (average change in erythropoietin levels per
week 25.5% [95% CI 0.4, 211] versus 214% [29.8, 218]
p=0.021, figure 3). These data suggest that erythropoietin had no
effect on the change in platelet levels upon iron therapy.
To confirm these unexpected findings we also analyzed a recent
independent cohort of patients (from FERGIcor; [16]). From the
total of 485 patients, platelet data were available from 448 patients
pre and post iron therapy. 228 patients had received 500–1200 mg
intravenous iron (50.9%) and 220 had received 1201–2000 mg
(49.1%). Half of the patients were treated with ferric carbox-
ymaltose (n=228, 50.9%), half with iron sucrose (n=220, 49.1%).
In this cohort, the platelet counts dropped from mean 383 (SD
139) G/L at study entry to 310 (101) G/L after treatment (table 2,
p,0.001) confirming the results from the initial analysis. The
change in platelet counts was independent of the iron compound
(figure 4A) and was dose-dependent (p,0.001, figure 4B). Similar
to the initial cohort, hemoglobin and iron parameters improved
but inflammation parameters did not change upon iron treatment
(table 2).
Discussion
The relative importance of iron deficiency for IBD-associated
anemia has been demonstrated in several studies. Here we
addressed the hypothesis that iron deficiency is also relevant for
IBD-associated thrombocytosis, a frequent finding in active IBD.
In both cohorts iron therapy was associated with a dose-dependent
normalization of elevated platelet counts. The decrease in platelets
was observed upon oral iron sulphate as well as intravenous iron
sucrose or ferric carboxymaltose treatment, and was independent
of erythropoietin. As inflammation parameters were low and did
not change during iron treatment we may conclude that IBD-
associated thrombocytosis in our cohorts is a result of iron
deficiency rather than systemic inflammation.
So far, the origin, the mechanism and consequences of
thrombocytosis in IBD have been unknown. This study is the first
to underline the relevance of iron deficiency in this setting. It is
important to state that iron therapy did not lower platelet counts
below physiological levels, indicating a regulatory rather than a
toxic effect. Also the effect was seen with different iron preparations,
which excludes a potential effect of the sugar carrier molecule (i.e.
sucrose, carboxymaltose). As platelet counts decreased continuous-
ly, we surmise that iron therapy reduced the dynamics of
megakaryopoiesis rather than changed the platelet half-life.
Figure 1. Primary dataset analysis. * FCM=ferric carboxymaltose. ** cumulative iron dose. Plt=platelets.
doi:10.1371/journal.pone.0034520.g001
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platelet dynamics though erythropoietin has been considered to
stimulate megakaryopoiesis [17]. In vitro, erythropoietin has no
effect on megakaryocytes and previous in vivo observations in
patients with chronic renal failure were also considered a
consequence of iron deficiency [18,19]. We may speculate that
iron deficiency has a direct effect on megakaryopoiesis to stimulate
platelet production for counteracting chronic bleeding.
Iron deficiency is one of the world’s most common and
potentially treatable health problems, nevertheless little is known
about its association with thrombocytosis. A Medline search
performed in February 2012 with ‘‘thrombocytosis’’ and ‘‘iron
deficiency’’ as search terms (limit English-language) identified 88
publications, mainly case reports. The first observations were
reported in 1904 [20] when the effect of severe hemorrhage on the
number of platelets was tested in rabbits. Several case reports linked
thrombosis, thrombocytosis and iron deficiency [21–27]. More
recently, this association was also discussed in patients with renal
failure [19,28]. However, this is the first study to demonstrate an
effect of iron therapy on platelets counts in humans. A second
Medline search performed in July 2011 with ‘‘thrombocytosis’’ and
‘‘IBD’’ as search terms identified 65 publications (limit English-
language). Again, several case reports about thrombosis or
thrombocytosis and IBD were identified [29–35]. Three studies
[36–38] showeda correlation withhigh disease activity, one studyin
children found thrombocytosis only in endoscopically confirmed
severe colitis [39]. In the study of Okun et al [40] the preoperative
thrombocytosis was a risk factor for postoperative chronic pouchitis,
however, in the study of Lian et al [41] it was not. Higher levels of
thrombopoietin were found [42] in patients with active disease
compared to inactive disease or healthy controls, however,
thrombopoietin levels did not correlate with platelet levels.
Thrombocytosis was shown to be a risk factor for steroid-
dependency in IBD [43] or lack of response to cyclosporine [44].
None of these studies evaluated iron parameters in the context of
thrombocytosis again underlining the originality of our study.
As to the retrospective nature of this study certain shortcomings
have to be considered. It is necessary to note that all patients had
anemia and IBD, a diagnostic combination that selected for the
presence of iron deficiency. Inclusion criteria and treatment
regimen (iron preparation and dosage) varied between studies
which might have had an impact on the outcome. Another
shortcoming is the absence of non-iron treatment control group.
Unfortunately, none of the studies from which the databases were
made available had such a control group. However, all iron
compounds (both oral and intravenous) showed a similar effect
indicating that it is a true iron rather than carrier effect. In
addition in all studies IBD medications were restricted by the
inclusion criteria and had to be stable before and during the
respective clinical trials. When testing leukocyte counts and C-
reactive protein no change was found. This indicates that the drop
in platelets is rather not caused by changes in inflammation but by
iron therapy itself. To strengthen our findings from the initial
cohort and to better control for these shortcomings the data were
confirmed in a second recently published cohort (FERGIcor) from
88 centers in 14 European countries. In this second cohort the
absolute platelet counts before iron treatment were not as high as
Figure 2. The changes in platelet counts upon iron therapy. (A)
Platelet counts pre and post iron replacement therapy according to iron
preparation (black column – iron sucrose n=122, grey column – ferric
carboxymaltose n=130, white column – iron sulphate n=56), p,0.001
pre vs. post for all iron preparations. (B) Mean drop in platelet counts
upon intravenous iron replacement therapy according to the cumula-
tive iron dose (p=0.002). Group 0–1200 mg n=97, group 1201–
2000 mg n=103, group 2001–3600 mg n=52. Error bars represent
standard deviation.
doi:10.1371/journal.pone.0034520.g002
Table 1. Changes in laboratory parameters upon iron
treatment (primary dataset n=307).
Pre iron Post iron N p value
Platelets G/L 425 (153) 320 (101) 308 ,0.001
Hemoglobin g/dL 8.8 (1.4) 12.2 (1.7) 308 ,0.001
Leukocytes G/L 8.9 (3.3) 8.7 (3.2) 121 0.577
C-reactive protein
mg/dL*
0.8 (0–15.2) 0.7 (0–24) 303 0.735
Ferritin mg/L* 6 (0–407) 68 (1–1920) 301 ,0.001
Transferrin
saturation %*
3 (0.5–49) 16.1 (1–98) 302 ,0.001
Continuous data given as mean (SD) or *median (range).
doi:10.1371/journal.pone.0034520.t001
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deficiency were also not as severe. Post iron therapy platelet counts
in both cohorts were comparable.
In summary, iron therapy normalizes elevated platelet counts in
patients with IBD-associated anemia. Thus, our study provides
initial evidence for a direct association between iron deficiency and
secondary thrombocytosis in IBD-associated anemia. In cancer
patients thrombocytosis is an independent risk factor for
thromboembolic events [45]. In IBD, predictive laboratory
parameters for thromboembolic events have not been evaluated.
It will be important to assess platelet activity and clot formation in
this setting. Further the role of secondary thrombocytosis in IBD
patients without iron deficiency needs clarification. It is tempting
to speculate that thrombocytosis in chronic disease arises on the
basis of an iron-deficient megakaryopoiesis, when iron is kept in
the monocyte-macrophage-system and thus is unavailable to the
bone marrow. Interventional studies in non-anemic IBD and
cancer patients are under way. If our hypothesis is true and iron
deficiency is causatively linked to thromboembolic events our work
has strong impact on medical practice in various fields including
orthopedic surgery, cancer, and chronic disease.
Methods
Study cohorts
The primary analysis was conducted at the Medical University
of Vienna between June and September 2008. The local ethics
committee had approved the protocol for the retrospective analysis
Figure 3. The changes of platelet counts and erythropoietin levels. Continuous drop in platelet counts (A, p=0.703) and serum
erythropoietin levels (B, p=0.021) in Crohn’s patients receiving iron sucrose (200–400 mg/week) and erythropoietin (150 mg/KG 3 times per week;
light column/line) or iron sucrose (200–400 mg/week) and placebo (dark column/line). N=20 for each group. Error bars represent standard deviation.
doi:10.1371/journal.pone.0034520.g003
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parameters before and after iron therapy (platelets, hemoglobin,
leukocytes, C-reactive protein, ferritin, transferrin saturation) were
obtained from four prospective clinical trials that had tested iron
therapy with and without erythropoietin in IBD:
1. In the ‘‘Crohn study’’[46], 40 patients with anemia and
Crohn’s disease receiving total dosages of up to 3600 mg iron
sucrose over 16 weeks were randomized to erythropoietin
treatment or placebo. Erythropoietin levels were measured in
serum samples (stored at 220uC) using a commercial
radioimmunoassay (Bio-Merieux, No ¨rtingen, Germany).
2. In the ‘‘Colitis study’’ [47], 20 patients with anemia and
ulcerative colitis were treated with a total amount of 2000 mg
iron sucrose over eight weeks. Non-responders to iron received
additionally erythropoietin.
3. In the ‘‘Predict study’’ [48], 63 patients with anemia and IBD
were treated with a total amount of 1200 mg iron sucrose over
four weeks.
4. In the ‘‘Ferric carboxymaltose study’’ [49], 200 patients with
anemia and IBD were randomized 2:1 to ferric carboxymaltose
(total median amount 1400 mg iron, n=137) or oral iron
sulphate (200 mg/day, n=63). The endpoints were evaluated
at week 12.
A second database from a recently published multicenter
clinical trial (FERGIcor; [16]) was made available in October
2011 and used as confirmation cohort. This trial was conducted
between October 2008 and December 2009. In the ‘‘FERGIcor
study’’, 485 patients with IBD-associated anemia were randomized
1:1 to ferric carboxymaltose (total mean amount 1380 mg iron,
n=244) or iron sucrose (total mean amount 1160 mg iron,
n=241). The endpoints were tested after 12 weeks. The study was
registered at: ClinicalTrials.gov (NCT00810030).
All five prospective studies were approved by the local ethic
committees as stated in the publications [16,46–49], for the
prospective studies written informed consent was obtained before
the screening visit.
Statistical analysis
Data were analyzed for distribution. Paired sample t-test or
Wilcoxon test for paired samples were used to compare values
before and after iron therapy as appropriate. Changes in platelet
counts according to iron dose were analyzed by analysis of
variance. Comparison of erythropoietin levels and platelet counts
over time was performed after a log-transformation because of
skewed distribution. The repeated weekly measurements were
summarized per patient by computing the slopes from individual
patient’s linear regression analyses. The slopes were compared
between groups by an independent samples t-test.
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Figure 4. The changes in platelet counts in the FERGIcor trial.
(A) Platelet counts pre and post iron therapy according to the iron
preparation (black column – ferric carboxymaltose n=228, grey column
– iron sucrose n=220), p,0.001 pre vs. post for both iron preparations.
(B) Mean drop in platelets upon iron therapy according to the
cumulative iron dose (p,0.001). Group 800–1200 mg n=228, group
1201–2000 mg n=220. Error bars represent standard deviation.
doi:10.1371/journal.pone.0034520.g004
Table 2. Changes in laboratory parameters upon iron
treatment (confirmation dataset: FERGIcor, n=448).
Pre iron Post iron N p value
Platelets G/L 383 (139) 310 (101) 448 ,0.001
Hemoglobin g/dL 10.2 (1.5) 12.8 (1.5) 427 ,0.001
Leukocytes G/L 7.2 (2.6) 7.0 (2.5) 400 0.142
C-reactive protein
mg/dL*
0.4 (0–6.0) 0.4 (0–5.8) 366 0.052
Ferritin mg/L* 8 (2–151) 72 (2–544) 420 ,0.001
Transferrin
saturation %*
5.6 (1.4–50) 19.1 (1.7–58) 402 ,0.001
Continuous data given as mean (SD) or *median (range).
doi:10.1371/journal.pone.0034520.t002
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